Theracryf (TCF)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

0.28p
   
  • Change Today:
      0.010p
  • 52 Week High: 1.22
  • 52 Week Low: 0.20
  • Currency: UK Pounds
  • Shares Issued: 2,148.96m
  • Volume: 13,766,713
  • Market Cap: £5.91m

Deal with Barclays    Trade now with Barclays Stockbrokers

Theracryf Overview

TheraCryf is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. The Company’s clinical asset is SFX-01, a patented sulforaphane-based medicine. Chronos’ neuropsychiatry assets use novel chemistry to address highly relevant targets in brain health and have composition of matter patent cover. The Group Company has the expertise to develop and commercialise the combined portfolio.

Key Personnel

CEO: Huw Jones
CFO: Toni Hänninen
Independent Non-Executive Director: Alan Barge
Non-Executive Chairman: Alastair Smith
Non-Executive Dir: Edward Wardle

Contact Details

Address: Liverpool Science Park Innovation Centre 2, 146 Brownlow Hill, Liverpool, Merseyside, United Kingdom , L3 5RF
Website: http://www.theracryf.com/

Listings

Sector: Pharma and Biotech(LSE)
Index: FTSE AIM All-Share
ISIN: GB00BSVYN304

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Theracryf Market Data

Currency UK Pounds
Share Price 0.28p
Change Today 0.010p
% Change 3.77 %
52 Week High 1.22
52 Week Low 0.20
Volume 13,766,713
Shares Issued 2,148.96m
Market Cap £5.91m

Theracryf Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
45.57% below the market average45.57% below the market average45.57% below the market average45.57% below the market average45.57% below the market average
48.94% above the sector average48.94% above the sector average48.94% above the sector average48.94% above the sector average48.94% above the sector average
Price Trend
93.22% below the market average93.22% below the market average93.22% below the market average93.22% below the market average93.22% below the market average
74.47% below the sector average74.47% below the sector average74.47% below the sector average74.47% below the sector average74.47% below the sector average
Income Not Available
Growth
16.56% below the market average16.56% below the market average16.56% below the market average16.56% below the market average16.56% below the market average
29.03% below the sector average29.03% below the sector average29.03% below the sector average29.03% below the sector average29.03% below the sector average

Theracryf Dividends

No dividends found

Trades for 28-May-2025

Time Volume / Share Price
16:04 50,352 @ 0.28p
15:54 1,060,534 @ 0.28p
15:52 58,195 @ 0.26p
15:34 300,000 @ 0.26p
15:32 17,605 @ 0.28p

Theracryf Key Personnel

CEO Huw Jones
CFO Toni Hänninen

Top of Page